Inventor · disambiguated record
Werner Scheuer
Also filed as: SCHEUER WERNER
22 granted patents·32 pending applications·230 citations·filing 1993–2023
96Inventor score
Files withHOFFMANN LA ROCHE27FRIESS THOMAS6BOEHRINGER MANNHEIM GMBH4BRINKMANN ULRICH4DOBOSZ MICHAEL3
Top patents by PatentIndex Score
54 records- 0197US8268314B2Bispecific anti-VEGF/anti-ANG-2 antibodiesBAEHNER MONIKA·Filed 2009·Granted Sep 18, 2012·70 cites·18 claims
- 0295US8133979B2Antibodies against human angiopoietin 2BRINKMANN ULRICH·Filed 2009·Granted Mar 13, 2012·19 cites·10 claims
- 0394US8703130B2Bispecific anti-VEGF/anti-ANG-2 antibodiesBAEHNER MONIKA·Filed 2012·Granted Apr 22, 2014·23 cites·12 claims
- 0492US9708396B2Bispecific anti-VEGF/anti-ANG-2 antibodiesHOFFMANN LA ROCHE·Filed 2014·Granted Jul 18, 2017·16 cites·17 claims
- 0592US8529901B2Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence labelHASMANN MAX·Filed 2008·Granted Sep 10, 2013·19 cites·2 claims
- 0692US8361747B2Antibodies against human angiopoietin 2HOFFMANN LA ROCHE·Filed 2012·Granted Jan 29, 2013·10 cites·4 claims
- 0791US9687568B2Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence labelHOFFMANN LA ROCHE·Filed 2013·Granted Jun 27, 2017·14 cites·23 claims
- 0891US8399626B2Antibodies against human angiopoietin 2BRINKMANN ULRICH·Filed 2012·Granted Mar 19, 2013·9 cites·5 claims
- 0987US9090700B2Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2FRIESS THOMAS·Filed 2010·Granted Jul 28, 2015·13 cites·9 claims
- 1087US8907069B2Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agentBRINKMANN ULRICH·Filed 2010·Granted Dec 9, 2014·7 cites·17 claims
- 1187US2023227543A1Antibodies against human angiopoietin 2HOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1284US9340609B2Antibodies against human angiopoietin 2HOFFMANN LA ROCHE·Filed 2012·Granted May 17, 2016·3 cites·5 claims
- 1384US2023399391A1Bispecific anti-vegf/anti-ang-2 antibodiesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1482US9050375B2Bi-specific digoxigenin binding antibodiesBRAMLAGE BIRGIT·Filed 2010·Granted Jun 9, 2015·6 cites·17 claims
- 1581US9109027B2Antibodies against human angiopoietin 2BRINKMANN ULRICH·Filed 2012·Granted Aug 18, 2015·2 cites·2 claims
- 1680US2020262904A1Antibodies against human angiopoietin 2HOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 1778US10584178B2Bispecific HER2 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Mar 10, 2020·2 cites·6 claims
- 1878US2021388071A1Antibodies against human angiopoietin 2HOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 1972US2021047394A1Bispecific anti-vegf/anti-ang-2 antibodiesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2070US9339560B2Method for determining the anti-tumor efficacy of monoclonal antibodiesBOSSENMAIER BIRGIT·Filed 2009·Granted May 17, 2016·0 cites·2 claims
- 2169US5716983AUse of coumarins and carbostyrils as PLA2 inhibitors, new coumarins and carbostyrils, processes for the production thereof and pharmaceutical agentsBOEHRINGER MANNHEIM GMBH·Filed 1994·Granted Feb 10, 1998·11 cites·8 claims
- 2269US2018282404A1Antibodies against human angiopoietin 2HOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 2367US9574016B2Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agentHOFFMANN LA ROCHE·Filed 2014·Granted Feb 21, 2017·0 cites·8 claims
- 2466US9073986B2Antibodies against human angiopoietin 2HOFFMANN LA ROCHE·Filed 2013·Granted Jul 7, 2015·0 cites·6 claims
- 2565US2020181280A1Modified pseudomonas exotoxin aTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICE·Filed 2019·Application pending·0 cites
- 2664US2017029493A1Antibodies against human angiopoietin 2HOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 2763US11787873B2Bispecific HER2 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2020·Granted Oct 17, 2023·0 cites·17 claims
- 2862US2018251536A1Tumor therapy with an anti-vegf antibodyHOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 2961US2017369566A1Bispecific anti-vegf/anti-ang-2 antibodiesHOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 3061US2015284457A1Antibodies against human angiopoietin 2HOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
- 3160US2008050385A1Tumor therapy with an anti-vegf antibodyFRIESS THOMAS·Filed 2007·Application pending·0 cites
- 3259US2015191535A1Bispecific, bivalent anti-vegf/anti-ang2 antibodiesHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
- 3357US2007224203A1Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2FRIESS THOMAS·Filed 2007·Application pending·0 cites
- 3457US2017239353A1Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2HOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 3557US2011223159A1Tumor therapy with an anti-vegf antibodyHOFFMANN LA ROCHE·Filed 2011·Application pending·0 cites
- 3657US2013183292A1Tumor therapy with an anti-vegf antibodyFRIESS THOMAS·Filed 2012·Application pending·0 cites
- 3755US2015239969A1Tumor therapy with an anti-vegf antibodyHOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
- 3854US2017051072A1Modified pseudomonas exotoxin aUS HEALTH·Filed 2016·Application pending·0 cites
- 3951US2015283238A1Tumor Therapy with an Antibody for Vascular Endothelial Growth Factor and an Antibody for Human Epithelial Growth Factor Receptor Type 2HOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
- 4051US2005153416A1Conjugates of the c domain of human gelatinase a and polyethylene glycol, methods of purification and uses thereofFiled 2003·Application pending·0 cites
- 4151US2017240626A1Bispecific, bivalent anti-vegf/anti-ang-2 antibodiesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 4251US2010285010A1Tumor therapy with an anti-vegf antibodyFRIESS THOMAS·Filed 2010·Application pending·0 cites
- 4346US5767249AMonoclonal antibodies against type I phospholipase A2 as a diagnostic and anti-inflammatory therapeutic agentBOEHRINGER MANNHEIM GMBH·Filed 1995·Granted Jun 16, 1998·4 cites·5 claims
- 4444US2008102069A1Tumor therapy with a combination of anti-her2 antibodiesFRIESS THOMAS·Filed 2007·Application pending·0 cites
- 4544US2019298861A1In vivo selection of therapeutically active antibodiesHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 4642US2014093458A1In vivo selection of therapeutically active antibodiesHOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
- 4741US2004132739A1Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereofFiled 2002·Application pending·0 cites
- 4838US2007009976A1Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibodyLENZ HELMUT·Filed 2006·Application pending·0 cites
- 4937US5856325ABenzotriazines, pharmaceutical compositions, and methods of using sameBOEHRINGER MANNHEIM GMBH·Filed 1993·Granted Jan 5, 1999·2 cites·10 claims
- 5036US2013236906A1Diagnostic method for the detection of cells ex vivoHOFFMANN LA ROCHE·Filed 2012·Application pending·0 cites
Showing the top 50 of 54 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Werner Scheuer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →